Thiazolidinediones: effects on insulin resistance and the cardiovascular system
Open Access
- 1 February 2008
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (4), 636-645
- https://doi.org/10.1038/sj.bjp.0707452
Abstract
Thiazolidinediones (TZDs) have been used for the treatment of hyperglycaemia in type 2 diabetes for the past 10 years. They may delay the development of type 2 diabetes in individuals at high risk of developing the condition, and have been shown to have potentially beneficial effects on cardiovascular risk factors. TZDs act as agonists of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) primarily in adipose tissue. PPAR-gamma receptor activation by TZDs improves insulin sensitivity by promoting fatty acid uptake into adipose tissue, increasing production of adiponectin and reducing levels of inflammatory mediators such as tumour necrosis factor-alpha (TNF-alpha), plasminogen activator inhibitor-1(PAI-1) and interleukin-6 (IL-6). Clinically, TZDs have been shown to reduce measures of atherosclerosis such as carotid intima-media thickness (CIMT). However, in spite of beneficial effects on markers of cardiovascular risk, TZDs have not been definitively shown to reduce cardiovascular events in patients, and the safety of rosiglitazone in this respect has recently been called into question. Dual PPAR-alpha/gamma agonists may offer superior treatment of insulin resistance and cardioprotection, but their safety has not yet been assured.Keywords
This publication has 123 references indexed in Scilit:
- Prevention of diabetesBMJ, 2006
- Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistancePharmacology & Therapeutics, 2006
- Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndromeJCI Insight, 2006
- Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activatorActa Diabetologica, 2005
- Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning studyAmerican Heart Journal, 2003
- Genetic analysis of four novel peroxisome proliferator activated receptor-γ splice variants in monkey macrophagesBiochemical and Biophysical Research Communications, 2002
- Structural and functional characterization of the mouse fatty acid translocase promoter: activation during adipose differentiationBiochemical Journal, 2001
- Peroxisome proliferator-activated receptor γ1 (PPARγ1) expresses in rat mesangial cells and PPARγ agonists modulate its differentiationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2000
- PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoterFEBS Letters, 1998
- mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.Genes & Development, 1994